Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.

[1]  Ri-zhen Huang,et al.  Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. , 2016, European journal of medicinal chemistry.

[2]  E. Novellino,et al.  Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. , 2014, European journal of medicinal chemistry.

[3]  Pengfei Liu,et al.  Facile and Versatile Synthesis of Alkyl and Aryl Isothiocyanates by Using Triphosgene and CoSolvent , 2013 .

[4]  E. Novellino,et al.  Development of peptidomimetic boronates as proteasome inhibitors. , 2013, European journal of medicinal chemistry.

[5]  S. Hecht,et al.  Synthesis of a new class of bis(thiourea)hydrazide pseudopeptides as potential inhibitors of β-sheet aggregation. , 2012, Organic letters.

[6]  T. Schirmeister,et al.  Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors , 2011, ChemMedChem.

[7]  J. Yadav,et al.  A novel trifunctional organocatalyst for the asymmetric aldol reaction: a facile enantioselective synthesis of β-hydroxyketones , 2011 .

[8]  James Lowe,et al.  Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.

[9]  Pinaki S. Bhadury,et al.  Synthesis and in vitro study of pseudo-peptide thioureas containing α-aminophosphonate moiety as potential antitumor agents. , 2010, European journal of medicinal chemistry.

[10]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[11]  S Iida,et al.  Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress , 2010, Leukemia.

[12]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[13]  Matthew Britton,et al.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. , 2009, Chemistry & biology.

[14]  James B Lorens,et al.  Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. , 2009, Blood.

[15]  J. Friedberg,et al.  BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress , 2009, Cancer biology & therapy.

[16]  M. Leippe,et al.  Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. , 2009, Journal of medicinal chemistry.

[17]  S. M. Gomha,et al.  A facile one-pot synthesis of 6,7,8,9-tetrahydrobenzo[4,5]thieno[2,3-d]-1,2,4-triazolo[4,5-a]pyrimidin-5-ones , 2009 .

[18]  Abigail G Doyle,et al.  Small-molecule H-bond donors in asymmetric catalysis. , 2007, Chemical reviews.

[19]  Richard Pazdur,et al.  Bortezomib for the Treatment of Mantle Cell Lymphoma , 2007, Clinical Cancer Research.

[20]  M. Groll,et al.  20S proteasome and its inhibitors: crystallographic knowledge for drug development. , 2007, Chemical reviews.

[21]  Afshin Samali,et al.  Mediators of endoplasmic reticulum stress‐induced apoptosis , 2006, EMBO reports.

[22]  A. Goldberg,et al.  Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.

[23]  R. Huber,et al.  Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2006, Annual review of medicine.

[25]  D. McConkey,et al.  Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. , 2005, Cancer research.

[26]  Y. Piao,et al.  Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 , 2005, Molecular Cancer Therapeutics.

[27]  T. Fujita,et al.  Proteasome inhibitors can alter the signaling pathways and attenuate the P‐glycoprotein‐mediated multidrug resistance , 2005, International journal of cancer.

[28]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[29]  L. Pfeffer,et al.  Interferon Induces NF-κB-inducing Kinase/Tumor Necrosis Factor Receptor-associated Factor-dependent NF-κB Activation to Promote Cell Survival* , 2005, Journal of Biological Chemistry.

[30]  Cun-Yu Wang,et al.  Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells , 2004, Molecular and Cellular Biology.

[31]  H. Yamaguchi,et al.  Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. , 2003, Cancer research.

[32]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[33]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[34]  Carlos Alemán,et al.  On the Ability of Modified Peptide Links to Form Hydrogen Bonds , 2001 .